The application of 5-bromodeoxyuridine in the management of CNS tumors.
A variety of clinical reports have described the application of the bromodeoxyuridine labeling index as an adjunct to conventional pathological examination of CNS tumors. This index has proven useful in predicting the clinical outcome associated with many such tumors. Furthermore, because of its efficacy as a radiosensitizing agent, bromodeoxyuridine (and the closely related iododeoxyuridine) has been used in combination with radiation therapy for malignant glial neoplasms, with some encouraging results. Although most studies suggest that bromodeoxyuridine is safe, there is evidence that this compound does have potential side-effects, including the observation that it is a mutagen and carcinogen in some experimental systems. A number of new alternative approaches for predicting the clinical outcome of CNS tumors has been developed based on an increased understanding of their molecular biology. However, until such approaches are better characterized, the clinical application of bromodeoxyuridine will continue to play an important role in predicting the clinical behavior of many CNS tumors.
Freese
A
A
Division of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia 19104.
O'Rourke
D
D
Judy
K
K
O'Connor
M J
MJ
D001932:Brain Neoplasms / Q000473:pathology* / Q000532:radiotherapy; D001973:Bromodeoxyuridine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D005910:Glioma / Q000473:pathology* / Q000532:radiotherapy; D006801:Humans; D008577:Meningeal Neoplasms / Q000473:pathology* / Q000532:radiotherapy; D008579:Meningioma / Q000473:pathology* / Q000532:radiotherapy
D001973:Bromodeoxyuridine